One of the earliest clinical trials of ADP-A2M4CD8 TCR was the SURPASS trial, and it started in 2019 with five patients who had various tumor types restricted to the HLA-A*02 haplotype and who were exposed to ADP-A2M4CD8 along with nivolumab or pembrolizumab [67,76]. Here, HLA-A is linked to neoplasm.